Table 6.

Univariate and multivariate analysis of factors predicting LRR in patients undergoing mastectomy after NAC

Parameters	Univariate analysis			Multivariate analysis
	LRR (n = 66)	No LRR (n = 549)	P value	Odds ratio	95% Confidence interval	P value
Age (years)			0.477
≦50	30 (9.8%)	275 (90.2%)
> 50	36 (11.6%)	274 (88.4%)
Clinical T stage			0.019
T1	3 (20.0%)	12 (80.0%)		1
T2	23 (9.1%)	229 (90.9%)		0.335	0.081–1.380	0.13
T3	9 (6.1%)	138 (93.9%)		0.228	0.050–1.035	0.055
T4	31 (15.4%)	170 (84.6%)		0.434	0.105–1.782	0.246
Clinical lymph node status			< 0.001
N0	1 (4.8%)	20 (95.2%)		1
N1	16 (5.7%)	264 (94.3%)		1.223	0.151–9.914	0.85
N2	49 (15.6%)	265 (84.4%)		2.983	0.380–23.421	0.299
SBR grade			0.07
1	1 (2.1%)	46 (97.9%)
2	25 (10.3%)	217 (89.7%)
3	37 (13.5%)	238 (86.5%)
Unknown	3 (5.9%)	48 (94.1%)
Histologic type			0.534
Invasive ductal carcinoma	64 (10.6%)	539 (89.4%)
Invasive lobular carcinoma	1 (16.7%)	5 (83.3%)
Mucinous carcinoma	0	3 (100.0%)
Others	1 (33.3%)	2 (66.7%)
Margin			> 0.999
Free	66 (10.1%)	541 (89.1%)
Positive	0	8 (100.0%)
ER			0.032
Positive	33 (8.6%)	349 (91.4%)		1
Negative	33 (14.2%)	200 (85.8%)		1.837	1.078–3.131	0.025
PR			0.105
Positive	29 (8.8%)	299 (91.2%)
Negative	37 (12.9%)	250 (87.1%)
HER2			0.51
Positive	27 (9.8%)	248 (90.2%)
Negative	39 (11.5%)	301 (88.5%)
Subtype			0.206
HR + /HER2−	26 (9.8%)	240 (90.2%)
HR + /HER2 +	11 (8.5%)	119 (91.5%)
HR−/HER2 +	16 (11.0%)	129 (89.0%)
HR−/HER2−	13 (17.6%)	61 (82.4%)
Neoadjuvant regimens			0.229
Anthracycline only	5 (19.2%)	21 (80.8%)
Taxane only	5 (11.4%)	39 (88.6%)
Anthracycline + Taxane	44 (11.6%)	336 (88.4%)
Chemotherapy + Target therapy	12 (7.3%)	153 (92.7%)
pCR			0.034
Yes	4 (4.4%)	87 (95.6%)		1
No	62 (11.8%)	462 (88.2%)		2.524	0.856–7.444	0.093

ER estrogen receptor, HR hormone receptor, HER-2 human epidermal growth factor receptor 2, LRR locoregional recurrence, NAC, neoadjuvant chemotherapy, pCR pathological complete response, PR progesterone receptor